Pharma & Bio
Lifestyle
Genosco, Tax Risk?… “Lecraza Is ‘Royalty Income’; Its Value Remains Unchanged”
Concerns about “tax risks” have been raised in some quarters of the financial investment, pharmaceutical, and biotech markets regarding Genosco, a subsidiary of OSCOTEC Inc.(039200)specializing in new…
Technology
Lee Chi-won, CEO of Mediintech: “We’ll Turn the Tables on Japan’s Dominance in the Endoscopy Market with Physical AI”
A South Korean company has thrown down the gauntlet with innovative technology in the flexible endoscope market, where three Japanese firms—Olympus, Pentax, and Fujifilm—dominate more than 95% of the …
Lifestyle
BL Pharmtech Hits Daily Limit…Samchundang Pharm Falls [K-bio pulse]
Investors in the biopharmaceutical sector continued to show strong interest in BL Pharmtech on July 2, driving its stock to the daily upper limit. The surge was fueled by growing expectations of tangi…
Lifestyle
BL Pharmtech Hits Daily Price Limit as Results Take Shape… SAM CHUN DANG PHARM CO. LTD Falls [Bio Spotlight]
On the 2nd, shares of BL Pharmtech(065170)hit the daily price limit again as investor interest in the pharmaceutical and biotech sector continued. BL Pharmtech’s stock price rose on expectations that …
Technology
Lim Jong-hoon Transfers Stake to PEF… Hanmi Group Management Control Dispute Enters a New Phase
The management control dispute at the HanmiPharm(128940) Group, which had appeared to have entered a lull for some time, has entered a new phase. This comes after Lim Jong-hoon, CEO of Hanmi Fine Chem…
Lifestyle
Dop Emerges as the Biggest Beneficiary of the Waste Management Act Amendment... Positive Signs for Reaching 500억 in Annual Revenue
DOP has emerged as the biggest beneficiary following the passage of a partial amendment to the Waste Management Act, which paves the way for the medical use of human fat. DOP, a company specializing i…
Business·Industry
AprilBio Co.,Ltd., Now Under TKG’s Wing, Launches R&D Expansion Drive with 3468억 in Funding
AprilBio Co.,Ltd.(397030)has welcomed TKG Huchems, an affiliate of the TKG Group, as its new controlling shareholder and has entered a phase of expanding its research and development (R&D) capabilitie…
Technology
[Space Biotech, Part 1] Why Are Big Pharma Companies Heading to Space? Microgravity Is Revolutionizing New Drug Development
Global Big Pharma companies are accelerating their efforts in the space medicine market, which is expected to grow to $1.6 billion (approximately 2.46 trillion won) by 2030. Starting with Merck (MSD) …
Technology
Kim Byung-soo, CEO of TR: “From National Screening Programs to Attracting Investment... Full-Scale Push into the Digital Lung Function Tester Market”
“For chronic conditions such as asthma or chronic obstructive pulmonary disease (COPD), early treatment is crucial. Seeing patients who, had their conditions been detected and managed early on, would …
Lifestyle
[BioUSA] Jeon Young-ho, CEO of EzQuris: “Expectations for a First-in-Class Drug; Background on Joint Research with AZ”
"The idea of developing antibody drugs as small molecules caught AstraZeneca's attention. Our goal is to create treatments that more patients can use while maintaining their efficacy."Jeon Young-ho, C…